From Nasdaq: 2025-01-17 05:47:00

Recursion Pharmaceuticals (NASDAQ: RXRX) is gaining attention for its AI-first approach to drug development and collaborations with major pharmaceutical companies like Roche, Bayer, and Sanofi. With $26 million in revenue and $752 million in cash, the company is well-positioned for growth, but lacks major upcoming catalysts for stock movement in 2025. Investors may need to hold onto the stock for three to five years to see significant returns, making it a long-term investment with potential volatility. While the field of AI-driven drug development shows promise, there is no rush to invest in Recursion at this time.



Read more at Nasdaq: Is Recursion Pharmaceuticals Stock a Buy?